{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:48:37Z","timestamp":1793879317662,"version":"4.7.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To determine the long-term functional and structural outcomes of intravitreal anti-VEGF therapy for macular neovascularization (MNV) in <jats:italic toggle=\"yes\">PRPH2<\/jats:italic>-associated retinopathy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Multicenter retrospective case series including patients with molecularly confirmed <jats:italic toggle=\"yes\">PRPH2<\/jats:italic>-associated retinopathy complicated by unilateral MNV. Best-corrected visual acuity (BCVA) and central subfield thickness (CST) were selected as outcome measures and compared between eyes with MNV undergoing anti-VEGF therapy and fellow eyes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Six patients affected by <jats:italic toggle=\"yes\">PRPH2<\/jats:italic>-associated retinopathy developed MNV at a median age of 55 years (range, 34 to 71). Two novel <jats:italic toggle=\"yes\">PRPH2<\/jats:italic> variants were found [c.499del p.(Cys150Phefs*3) and c.660dup p.(Pro221Alafs*80)]. In all patients, the phenotype was characterized by a pattern dystrophy with multifocal flecks. At baseline, eyes with MNV had a median BCVA (logMAR) of 0.2 (range, 0.2 to 0.7), corresponding to 20\/32 Snellen, while the median CST was 320 <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>m (range, 228 to 362). After a median follow-up of 6.2 years and 5.5 injections per patient, 5 eyes (83%) retained a BCVA of at least 20\/32 Snellen, while CST decreased by a median of \u221269 <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>m (range, \u2212117 to +15). No additional CST thinning was observed in eyes with MNV compared with their fellow eyes. In 4 eyes (67%), OCT angiography revealed large neovascular networks growing below the retinal pigment epithelium that persisted after resolution of exudation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>A favorable long-term outcome can be obtained in <jats:italic toggle=\"yes\">PRPH2<\/jats:italic>-associated retinopathy complicated by MNV when timely intravitreal anti-VEGF therapy is administered. Further research is needed to understand the significance of subretinal pigment epithelium neovascular networks.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000004476","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T16:02:41Z","timestamp":1743782561000},"page":"1548-1553","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["LONG-TERM OUTCOMES OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR MACULAR NEOVASCULARIZATION IN PRPH2-ASSOCIATED RETINOPATHY"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4023-5387","authenticated-orcid":false,"given":"Lorenzo","family":"Bianco","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy;"},{"name":"Sorbonne Universit\u00e9, INSERM, CNRS, Institut de la Vision, Paris, France;"},{"name":"CHNO des Quinze-Vingts, Centre de R\u00e9f\u00e9rence Maladies Rares REFERET, INSERM-DGOS CIC1423, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Audo","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, CNRS, Institut de la Vision, Paris, France;"},{"name":"CHNO des Quinze-Vingts, Centre de R\u00e9f\u00e9rence Maladies Rares REFERET, INSERM-DGOS CIC1423, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Antropoli","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy;"},{"name":"Sorbonne Universit\u00e9, INSERM, CNRS, Institut de la Vision, Paris, France;"},{"name":"CHNO des Quinze-Vingts, Centre de R\u00e9f\u00e9rence Maladies Rares REFERET, INSERM-DGOS CIC1423, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael C.","family":"Heath Jeffery","sequence":"additional","affiliation":[{"name":"Centre for Ophthalmology and Visual Science, The University of Western Australia, Perth, Australia;"},{"name":"Ocular Tissue Engineering Laboratory, Lions Eye Institute, Nedlands, Australia;"},{"name":"Royal Victorian Eye and Ear Hospital, East Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred K.","family":"Chen","sequence":"additional","affiliation":[{"name":"Centre for Ophthalmology and Visual Science, The University of Western Australia, Perth, Australia;"},{"name":"Ocular Tissue Engineering Laboratory, Lions Eye Institute, Nedlands, Australia;"},{"name":"Royal Victorian Eye and Ear Hospital, East Melbourne, Australia;"},{"name":"Australian Inherited Retinal Disease Registry and DNA Bank, Department of Medical Technology and Physics, Sir Charles Gairdner Hospital, Nedlands, Australia;"},{"name":"Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Arrigo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy;"},{"name":"Eye Repair Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad M.","family":"Mansour","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, American University of Beirut, Beirut, Lebanon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Zeitz","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, CNRS, Institut de la Vision, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Battaglia Parodi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250723","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/13816810.2021.1913610","article-title":"Inherited retinal diseases are the most common cause of blindness in the working-age population in Australia","volume":"42","author":"Heath Jeffery","year":"2021","journal-title":"Ophthalmic Genet"},{"key":"R2-20250723","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.ophtha.2020.04.008","article-title":"Genetic basis of inherited retinal disease in a molecularly characterized cohort of more than 3000 families from the United Kingdom","volume":"127","author":"Pontikos","year":"2020","journal-title":"Ophthalmology"},{"key":"R3-20250723","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/354478a0","article-title":"A three-base-pair deletion in the peripherin\u2013RDS gene in one form of retinitis pigmentosa","volume":"354","author":"Farrar","year":"1991","journal-title":"Nature"},{"key":"R4-20250723","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/354480a0","article-title":"Mutations in the human retinal degeneration slow gene in autosomal dominant retinitis pigmentosa","volume":"354","author":"Kajiwara","year":"1991","journal-title":"Nature"},{"key":"R5-20250723","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/hmg\/3.7.1195","article-title":"Asn244His mutation of the peripherin\/RDS gene causing autosomal dominant cone-rod degeneration","volume":"3","author":"Nakazawa","year":"1994","journal-title":"Hum Mol Genet"},{"key":"R6-20250723","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0002-9394(14)70627-0","article-title":"Autosomal dominant central areolar choroidal dystrophy caused by a mutation in codon 142 in the peripherin\/RDS gene","volume":"121","author":"Hoyng","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"R7-20250723","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.preteyeres.2008.01.002","article-title":"The spectrum of retinal dystrophies caused by mutations in the peripherin\/RDS gene","volume":"27","author":"Boon","year":"2008","journal-title":"Prog Retin Eye Res"},{"key":"R8-20250723","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ajo.2024.10.025","article-title":"PRPH2-associated retinal diseases: a systematic review of phenotypic findings","volume":"271","author":"AlAshwal","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"R9-20250723","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1167\/iovs.65.5.22","article-title":"Retinal dystrophies associated with peripherin-2: genetic spectrum and novel clinical observations in 241 patients","volume":"65","author":"Heath Jeffery","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R10-20250723","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1167\/iovs.61.6.61","article-title":"Optical coherence tomography angiography quantitative assessment of macular neovascularization in best vitelliform macular dystrophy","volume":"61","author":"Parodi","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R11-20250723","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.oret.2022.11.014","article-title":"Choroidal neovascularization is common in best vitelliform macular dystrophy and plays a role in vitelliform lesion evolution","volume":"7","author":"Han","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"R12-20250723","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/11206721231166434","article-title":"Multimodal imaging in best vitelliform macular dystrophy: literature review and novel insights","volume":"34","author":"Bianco","year":"2024","journal-title":"Eur J Ophthalmol"},{"key":"R13-20250723","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ajo.2008.03.024","article-title":"Clinical course and treatment outcomes of sorsby fundus dystrophy","volume":"146","author":"Sivaprasad","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R14-20250723","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/bjo.2008.150151","article-title":"Republished review. [corrected] Late-onset retinal macular degeneration: clinical insights into an inherited retinal degeneration","volume":"85","author":"Borooah","year":"2009","journal-title":"Postgrad Med J"},{"key":"R15-20250723","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/s41433-019-0348-8","article-title":"Multimodal imaging of late-onset retinal degeneration complicated by bilateral choroidal neovascularization","volume":"33","author":"Mandal","year":"2019","journal-title":"Eye (Lond)."},{"key":"R16-20250723","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1167\/iovs.05-1600","article-title":"Maculopathy due to the R345W substitution in fibulin-3: distinct clinical features, disease variability, and extent of retinal dysfunction","volume":"47","author":"Michaelides","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R17-20250723","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ajo.2016.12.027","article-title":"Choroidal neovascularization in malattia leventinese diagnosed using optical coherence tomography angiography","volume":"176","author":"Serra","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"R18-20250723","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ajo.2024.03.026","article-title":"Anti-VEGF treatment for secondary neovascularization in pseudoxanthoma elasticum - age of onset, treatment frequency, and visual outcome","volume":"265","author":"Raming","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"R19-20250723","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2023.07.007","article-title":"Macular neovascularization in inherited retinal diseases: a review","volume":"69","author":"Heath Jeffery","year":"2024","journal-title":"Surv Ophthalmol"},{"key":"R20-20250723","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1097\/IAE.0000000000003205","article-title":"Massive advancing nonexudative type 1 choroidal neovascularization in CTRP5 late-onset retinal degeneration: longitudinal findings on multimodal imaging and implications for age-related macular degeneration","volume":"41","author":"Keenan","year":"2021","journal-title":"Retina"},{"key":"R21-20250723","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.oret.2024.08.002","article-title":"Prevalence, features, and outcomes of type 1 neovascularization in eyes with angioid streaks","volume":"9","author":"Cicinelli","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"R22-20250723","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1136\/bjo.2004.062695","article-title":"Genetic and phenotypic heterogeneity in pattern dystrophy","volume":"89","author":"Francis","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R23-20250723","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.3390\/genes12111817","article-title":"Genetic and phenotypic landscape of PRPH2-associated retinal dystrophy in Japan","volume":"12","author":"Oishi","year":"2021","journal-title":"Genes (Basel)"},{"key":"R24-20250723","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.3390\/diagnostics12081851","article-title":"Multimodal study of PRPH2 gene-related retinal phenotypes","volume":"12","author":"Antonelli","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"R25-20250723","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.oret.2022.12.008","article-title":"PRPH2-Associated retinopathy: novel variants and genotype\u2013phenotype correlations","volume":"7","author":"Bianco","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"R26-20250723","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00006982-200304000-00006","article-title":"Photodynamic therapy for choroidal neovascularization associated with pattern dystrophy","volume":"23","author":"Battaglia Parodi","year":"2003","journal-title":"RETINA"},{"key":"R27-20250723","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ajo.2006.01.038","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization secondary to reticular pattern dystrophy: three-year results of an uncontrolled, prospective case series","volume":"141","author":"Parodi","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R28-20250723","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/112067210701700620","article-title":"Intravitreal bevacizumab for adult-onset vitelliform dystrophy: a case report","volume":"17","author":"Montero","year":"2007","journal-title":"Eur J Ophthalmol"},{"key":"R29-20250723","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1167\/iovs.10-5237","article-title":"Intravitreal bevacizumab for subfoveal choroidal neovascularization associated with pattern dystrophy","volume":"51","author":"Parodi","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R30-20250723","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1167\/tvst.10.14.34","article-title":"Conversion of central subfield thickness measurements of diabetic macular edema across Cirrus and spectralis optical coherence tomography instruments","volume":"10","author":"Sun","year":"2021","journal-title":"Transl Vis Sci Technol"},{"key":"R31-20250723","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1097\/IAE.0b013e31824b32e4","article-title":"Pattern dystrophy with high intrafamilial variability associated with Y141C mutation in the peripherin\/rds gene and successful treatment of subfoveal CNV related to multifocal pattern type with anti-vegf (ranibizumab) intravitreal injections","volume":"32","author":"Vaclavik","year":"2012","journal-title":"Retina"},{"key":"R32-20250723","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1080\/13816810.2021.1952617","article-title":"Treatment and longitudinal follow-up of CNV associated with pattern dystrophy with novel PRPH2 variant","volume":"42","author":"Xu","year":"2021","journal-title":"Ophthalmic Genet"},{"key":"R33-20250723","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"R34-20250723","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/bjophthalmol-2015-308166","article-title":"Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study","volume":"100","author":"Holz","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"R35-20250723","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet (London, England)"},{"key":"R36-20250723","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","article-title":"Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials","volume":"121","author":"Grunwald","year":"2014","journal-title":"Ophthalmology"},{"key":"R37-20250723","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ajo.2023.03.033","article-title":"Ten-year incidence of fibrosis and risk factors for its development in neovascular age-related macular degeneration","volume":"252","author":"Romano","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"R38-20250723","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.oret.2022.12.002","article-title":"Incidence and risk factors of visual impairment in patients with angioid streaks and macular neovascularization","volume":"7","author":"Cicinelli","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"R39-20250723","doi-asserted-by":"crossref","first-page":"NP98","DOI":"10.1177\/11206721211004396","article-title":"OCT-angiography assessing quiescent and active choroidal neovascularization in retinitis pigmentosa associated with PRPH2 pathogenic variant","volume":"32","author":"Falfoul","year":"2022","journal-title":"Eur J Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T02:00:14Z","timestamp":1753236014000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004476","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}